Eagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research note published on Friday. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Down 1.0 %

Shares of NASDAQ:EGRX opened at $4.05 on Friday. Eagle Pharmaceuticals has a 52-week low of $3.21 and a 52-week high of $19.14. The stock has a market cap of $52.60 million, a P/E ratio of 3.43 and a beta of 0.51. The business’s 50 day moving average is $4.86 and its 200 day moving average is $5.01.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of EGRX. DGS Capital Management LLC bought a new position in Eagle Pharmaceuticals in the fourth quarter worth approximately $60,000. Los Angeles Capital Management LLC lifted its holdings in Eagle Pharmaceuticals by 68.1% during the fourth quarter. Los Angeles Capital Management LLC now owns 91,262 shares of the specialty pharmaceutical company’s stock worth $477,000 after buying an additional 36,982 shares during the period. BNP Paribas Financial Markets lifted its holdings in Eagle Pharmaceuticals by 378.7% during the fourth quarter. BNP Paribas Financial Markets now owns 88,685 shares of the specialty pharmaceutical company’s stock worth $464,000 after buying an additional 70,158 shares during the period. Jump Financial LLC lifted its holdings in Eagle Pharmaceuticals by 172.0% during the fourth quarter. Jump Financial LLC now owns 38,900 shares of the specialty pharmaceutical company’s stock worth $203,000 after buying an additional 24,600 shares during the period. Finally, Trexquant Investment LP lifted its holdings in Eagle Pharmaceuticals by 88.0% during the fourth quarter. Trexquant Investment LP now owns 126,282 shares of the specialty pharmaceutical company’s stock worth $660,000 after buying an additional 59,095 shares during the period. Institutional investors own 85.36% of the company’s stock.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.